 Alanine Transaminase
"Alanine Transaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
| Descriptor ID |
D000410
|
| MeSH Number(s) |
D08.811.913.477.700.100
|
| Concept/Terms |
Alanine Transaminase- Alanine Transaminase
- Transaminase, Alanine
- Glutamic-Alanine Transaminase
- Glutamic Alanine Transaminase
- Transaminase, Glutamic-Alanine
- Alanine-2-Oxoglutarate Aminotransferase
- Alanine 2 Oxoglutarate Aminotransferase
- Aminotransferase, Alanine-2-Oxoglutarate
- Alanine Aminotransferase
- Aminotransferase, Alanine
- Glutamic-Pyruvic Transaminase
- Glutamic Pyruvic Transaminase
- Transaminase, Glutamic-Pyruvic
|
Below are MeSH descriptors whose meaning is more general than "Alanine Transaminase".
Below are MeSH descriptors whose meaning is more specific than "Alanine Transaminase".
This graph shows the total number of publications written about "Alanine Transaminase" by people in this website by year, and whether "Alanine Transaminase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1985 | 0 | 1 | 1 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1990 | 0 | 5 | 5 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 4 | 4 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 4 | 5 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 6 | 7 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 3 | 3 | | 2012 | 0 | 4 | 4 | | 2013 | 1 | 2 | 3 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Alanine Transaminase" by people in Profiles.
-
Lu Y, Pike JR, Selvin E, Mosley T, Palta P, Sharrett AR, Thomas A, Loehr L, Sidney Barritt A, Hoogeveen RC, Heiss G. Low Liver Enzymes and Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study. J Alzheimers Dis. 2021; 79(4):1775-1784.
-
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 12 31; 16(1):48-58.
-
Siddiqui MB, Patel S, Bhati C, Reichman T, Williams K, Driscoll C, Liptrap E, Rinella ME, Sterling RK, Siddiqui MS. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901.
-
Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
-
Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651.
-
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
-
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 07; 18(7):946-957.
-
Tapper EB, Saini SD, Sengupta N. Extensive testing or focused testing of patients with elevated liver enzymes. J Hepatol. 2017 02; 66(2):313-319.
-
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
-
Celis K, Shuldiner S, Haverfield EV, Cappell J, Yang R, Gong DW, Chung WK. Loss of function mutation in glutamic pyruvate transaminase 2 (GPT2) causes developmental encephalopathy. J Inherit Metab Dis. 2015 Sep; 38(5):941-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|